GCG and type 2 diabetes mellitus: As DPP4 is known to inactivate the incretin glucagon-like peptide-1 (GLP-1), the discovery of new DPP4 inhibitors is considered an indirect approach to increase GLP-1 levels and thus to manage diabetes mellitus type 2.